Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Summary not available.
Alcon (SIX/NYSE: ALC) and STAAR Surgical (NASDAQ: STAA) agreed to adjourn STAAR’s Special Meeting of Stockholders originally scheduled for October 23, 2025 in connection with STAAR’s merger agreement with Alcon. The Special Meeting is adjourned until 8:30 a.m. Pacific Time on November 6, 2025. No other business will be conducted at the Special Meeting. The record date for stockholders eligible to vote remains the close of business on September 12, 2025. Stockholders with voting questions are directed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at toll-free +1 877-750-8233 or banks/brokers +1 212-750-5833.
Yunqi Capital (NASDAQ:STAA), a 5.1% STAAR shareholder, urged the board to hold the special shareholder meeting on October 23, 2025 and reiterated its opposition to the proposed sale to Alcon. Yunqi criticized STAAR’s pre-merger process and called recent company disclosures “disingenuous.”
Yunqi highlighted preliminary Q3 results: China revenue YTD $142.6M, estimated Q3 China revenue ≈$54.4M, $25.6M consignment revenue, and said Q3 sales exceeded consensus by 2.8%. Yunqi projects China sales of $180–200M for 2026 versus STAAR’s $160M guide and flagged missing margin/profit detail before the vote.
Summary not available.
Broadwood Partners (NASDAQ: STAA), which holds 27.5% of STAAR outstanding shares, sent a letter to STAAR Surgical’s board on October 17, 2025 urging directors to allow a timely shareholder vote on the proposed sale to Alcon (NYSE: ALC). Broadwood urges shareholders to vote AGAINST the acquisition announced August 5, 2025, arguing the board pursued a poorly designed process and an inadequate price.
Broadwood warns the board against delaying the October 23, 2025 vote or issuing misleading statements, and says shareholders and proxy advisors oppose the deal; it calls for the board to accept the vote result and work with shareholders if the transaction is rejected.
Summary not available.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reiterated its board's unanimous recommendation that stockholders vote FOR the merger with Alcon on the white proxy card.
Key points: Alcon's offer is $28.00 per share in cash (a 59% premium to the 90-day VWAP). STAAR contrasts this with Broadwood's position and a prior price of $18.49 per share, warning a vote against could invite control shifts and valuation pressure. Stockholders are urged to contact STAAR's proxy solicitor for voting assistance.
Summary not available.
Defender Capital, a long-term shareholder owning approximately 1.5% of STAAR Surgical (NASDAQ: STAA), announced on October 7, 2025 its opposition to the proposed sale of STAAR to Alcon (NYSE: ALC) for $28 per share. Defender said the $28 price significantly undervalues STAAR, noting the STAAR board rejected a prior $58 per share cash offer from Alcon sixteen months earlier. Defender cited recent positive projections and outlook from STAAR management and argued there is no compelling reason to sell at the proposed valuation. Defender described the transaction as ill-advised and said it does not reflect STAAR’s standalone prospects.
FAQ
What is the current stock price of Alcon (ALC)?
What is the market cap of Alcon (ALC)?
